M
Marie Mandron
Researcher at Technion – Israel Institute of Technology
Publications - 7
Citations - 312
Marie Mandron is an academic researcher from Technion – Israel Institute of Technology. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 2, co-authored 2 publications receiving 282 citations.
Papers
More filters
Journal ArticleDOI
Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration.
Benoit Favier,Antoine Alam,Pauline Barron,Jacques Bonnin,Patricia Laboudie,Pierre Fons,Marie Mandron,J. P. Hérault,Gera Neufeld,Pierre Savi,Jean-Marc Herbert,Francoise Bono +11 more
TL;DR: The data indicate that NRP2 acts as a coreceptor that enhances human endothelial cell biological responses induced by VEGF-A and VEGf-C, and is correlated with an enhancement of the VEGFR-2 phosphorylation threshold.
Journal ArticleDOI
Specific Inhibition of the VEGFR-3 Tyrosine Kinase by SAR131675 Reduces Peripheral and Tumor Associated Immunosuppressive Myeloid Cells.
Nicolas Espagnolle,Pauline Barron,Marie Mandron,Isabelle Blanc,Jacques Bonnin,Magali Agnel,Erwan Kerbelec,Jean Pascal Herault,Pierre Savi,Franç oise Bono,Antoine Alam +10 more
TL;DR: Results demonstrate that the specific VEGFR-3 inhibitor SAR131675 exerts its anti tumoral activity by acting on different players that orchestrate immunosuppression and cancer progression in a tumoral context: MDSCs in peripheral lymphoid organs and TAMs infiltrating the tumor.
Journal ArticleDOI
Therapeutic and prophylactic treatment with a virus-specific antibody is highly effective in rodent models of Chikungunya infection and disease.
Justin G. Julander,Nicole Christyn Anderson,Nicole N. Haese,Takeshi Andoh,Daniel N. Streblow,Pierre Cortez,Kara Carter,X. Marniquet,Hugh Watson,Marie Mandron +9 more
TL;DR: In this article , the authors demonstrate the efficacy of a CHIKV-specific antibody in the prophylactic and therapeutic treatment of chikungunya virus in mouse models of disease.
Journal ArticleDOI
Abstract 3203: Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial
Michael R. Paillasse,James Garner,Michael Fitzgerald,Lise Davenne,Pierre-Benoit Ancey,Celine Poussereau-Pomie,Michael Esquerre,Gaelle Badet,Joēl Tuyaret,Marie Mandron,Philippe Rochaix,Maha Ayyoub,Clara-Maria Scarlata,Christine Ménétrier-Caux,Chrsitophe Caux,Philippe A. Cassier,Jean-Pierre Delord,Carlos Roca,Pierre Fons +18 more
TL;DR: Cutting edge biomarkers strategy to provide early insights into activity of EVT-801, a novel selective VEGFR-3 inhibitor that targets tumor angiogenesis during the FIH clinical trial is proposed.
Journal ArticleDOI
Household clustering supports a novel chemoprophylaxis trial design for a mosquito-borne viral disease.
TL;DR: In this paper , the authors proposed the application of a household transmission model as used in testing drugs against respiratory viruses against chikungunya and other Aedes mosquito-borne viral infections.